News
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod
The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.
News
Bayer's Hyrnuo moves first-line for lung cancer in China
Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News
Oral Wegovy bolsters Novo in Q3
Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy.
News
UK women's health firm Theramex sold for around £2.2bn
Theramex, a UK-based specialty pharma company focusing on women's health, is changing hands in a private equity deal said to be worth around £2.2bn.
News
What do midterms mean for Trump's pharma and health agenda?
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
